跳转至内容
Merck
CN

1356803

USP

Lactulose

United States Pharmacopeia (USP) Reference Standard

别名:

4-O-β-D-Galactopyranosyl-D-fructofuranose, 4-O-β-D-Galactopyranosyl-D-fructose

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C12H22O11
化学文摘社编号:
分子量:
342.30
Beilstein:
93773
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

pharmaceutical primary standard

API类

lactulose

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO)O[C@@](O)(CO)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O

InChI

1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2/t4-,5-,6+,7+,8-,9-,10+,11+,12+/m1/s1

InChI key

JCQLYHFGKNRPGE-WJONTELPSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Lactulose USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Lactulose Concentrate
  • Lactulose Solution

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

涉药品监管产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

J Zhao et al.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 26(6), 794-802 (2014-03-20)
Small intestinal bacterial overgrowth (SIBO) may be a cause of irritable bowel syndrome (IBS); however, current investigations have important limitations. We aimed to identify clinically relevant diagnostic criteria for SIBO based on lactulose hydrogen breath test (LHBT) alone and combined
A A Guerra-Ordaz et al.
Applied and environmental microbiology, 80(16), 4879-4886 (2014-06-08)
The potential of a prebiotic oligosaccharide lactulose, a probiotic strain of Lactobacillus plantarum, or their synbiotic combination to control postweaning colibacillosis in pigs was evaluated using an enterotoxigenic Escherichia coli (ETEC) K88 oral challenge. Seventy-two weanlings were fed four diets:
Kostan W Reisinger et al.
Journal of pediatric gastroenterology and nutrition, 59(6), 720-724 (2014-08-12)
The incidence of necrotizing enterocolitis (NEC) is higher in formula-fed babies than in breast-fed babies, which may be caused by breast-feeding-induced gut maturation. The effect of breast-feeding on gut maturation has been widely studied in animal models. This study aimed
Jun Fang et al.
Journal of pharmaceutical sciences, 103(10), 3235-3243 (2014-07-22)
Bacteria of micrometer size could accumulate in tumor based on enhanced permeability and retention (EPR) effect. We report here Lactobacillus casei (L. casei), a nonpathogenic facultatively anaerobic bacterium, preferentially accumulated in tumor tissues after intravenously (i.v.) injection; at 24 h
M R Clausen et al.
Drugs, 53(6), 930-942 (1997-06-01)
Lactulose is one of the most frequently utilised agents in the treatment of constipation and hepatic encephalopathy because of its efficacy and good safety profile. The key to understanding the possible modes of action by which lactulose achieves its therapeutic

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持